Biotechnology US biotech firm Cell Therapeutics (Nasdaq: CTIC) revealed this week in a filing with the Securities Exchange Commission that, on June 17, 2013, the US Food and Drug Administration notified the company that a partial clinical hold has been placed on tosedostat (IND 075503), its aminopeptidase inhibitor under development for the treatment of blood-related cancers. Myocarditis - an inflammation of heart muscle. Cell Thera's shares reacted with an initial fall of 11% $1.09, but rebounded to $1.13 Tuesday before markets opened. 25 June 2013